Ratio Therapeutics Secures $70 Million in Latest Series C Funding Round

Ratio Therapeutics secured $70 million in its latest Series C, adding another data point to the Healthcare & Life Sciences funding market.

Ratio Therapeutics Raises $70 million in Funding

Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure. "We've tracked that progress closely, and our investment reflects our strong conviction in Ratio's platform and its potential to change outcomes for patients." About Ratio Therapeutics Ratio Therapeutics, Inc. is a clinical-stage pharmaceutical company that systematically engineers radiopharmaceuticals to optimize therapeutic index and develop best-in-class cancer treatments.

Investors Behind the Funding

The round was backed by Ratio's Trillium pharmacokinetic tuning technology. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Ratio Therapeutics operates in Healthcare & Life Sciences. Ratio Therapeutics's financing adds to recent private-market activity.

Strategic Use of Funds

Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure.

Looking Ahead

This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead,

Source reference: original announcement/article.